Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial

BACKGROUND: In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once‐weekly resulted in a nonsignificant reduction in major adverse cardiovascular events (MACEs) and a nominal 14% reduction in all‐cause mortality in 14 752 patients with type 2 diabetes mellitus (T2DM) with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mentz, Robert J., Bethel, M. Angelyn, Merrill, Peter, Lokhnygina, Yuliya, Buse, John B., Chan, Juliana C., Felício, João S., Goodman, Shaun G., Choi, Jasmine, Gustavson, Stephanie M., Iqbal, Nayyar, Lopes, Renato D., Maggioni, Aldo P., Öhman, Peter, Pagidipati, Neha J., Poulter, Neil R., Ramachandran, Ambady, Reicher, Barry, Holman, Rury R., Hernandez, Adrian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404902/
https://www.ncbi.nlm.nih.gov/pubmed/30371301
http://dx.doi.org/10.1161/JAHA.118.009304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404902/
https://www.ncbi.nlm.nih.gov/pubmed/30371301
http://dx.doi.org/10.1161/JAHA.118.009304

Ejemplares similares